Sera Prognostics (Sera Prognostics) Days Sales Outstanding : 350.53 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Days Sales Outstanding?

Sera Prognostics's average Accounts Receivable for the three months ended in Dec. 2023 was $0.16 Mil. Sera Prognostics's Revenue for the three months ended in Dec. 2023 was $0.04 Mil. Hence, Sera Prognostics's Days Sales Outstanding for the three months ended in Dec. 2023 was 350.53.

The historical rank and industry rank for Sera Prognostics's Days Sales Outstanding or its related term are showing as below:

SERA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 10.14 Med: 64.54 Max: 169.62
Current: 169.62

During the past 5 years, Sera Prognostics's highest Days Sales Outstanding was 169.62. The lowest was 10.14. And the median was 64.54.

SERA's Days Sales Outstanding is ranked worse than
79.56% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.32 vs SERA: 169.62

Sera Prognostics's Days Sales Outstanding increased from Dec. 2022 (154.42) to Dec. 2023 (350.53).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Sera Prognostics Days Sales Outstanding Historical Data

The historical data trend for Sera Prognostics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Days Sales Outstanding Chart

Sera Prognostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

10.14

21.90

64.54

95.34

162.82

Sera Prognostics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial												154.42	106.31	104.97	345.45	350.53

Competitive Comparison of Sera Prognostics's Days Sales Outstanding

For the Diagnostics & Research subindustry, Sera Prognostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sera Prognostics's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sera Prognostics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Days Sales Outstanding falls into.

Sera Prognostics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Sera Prognostics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.113	+	0.16)	/	2 )	/	0.306	*	365
=	0.1365					/	0.306	*	365
=	162.82

Sera Prognostics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.155	+	0.16)	/	2 )	/	0.041	*	365 / 4
=	0.1575					/	0.041	*	365 / 4
=	350.53

Sera Prognostics (NAS:SERA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Sera Prognostics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Sera Prognostics (Sera Prognostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109

Website

https://www.seraprognostics.com

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.

Executives

John J. Boniface	officer: Chief Scientific Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson	officer: General Counsel	320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts	officer: Chief Financial Officer	2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison	officer: Chief Information Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley	officer: Chief Medical Officer	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence	director	C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt	director	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney	officer: Chief Data Officer	2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc	10 percent owner	239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin	officer: VP OF Q/R & HIPPA PRIV. OFF	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare	officer: Chief Commercial Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109